Moneycontrol
Oct 12, 2017 01:34 PM IST | Source: Moneycontrol.com

Cadila Healthcare gains 2% on USFDA nod for Desvenlafaxine tablets

The drug is used to treat major depression and will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.

Cadila Healthcare gains 2% on USFDA nod for Desvenlafaxine tablets

Moneycontrol News

Shares of Cadila Healthcare added 2.4 percent intraday as it has received USFDA nod for Desvenlafaxine tablets.

Zydus Cadila has received final approval from the USFDA to market Desvenlafaxine extended-release tablets, 50 mg and 100 mg.

The drug is used to treat major depression and will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.

The group now has more than 160 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

The meeting of the board of directors of the company will be held on November 14 to consider apart from other agenda items to approve the unaudited financial results for the quarter / half year ended on September 30, 2017.

At 13:31 hrs Cadila Healthcare was quoting at Rs 497.45, up Rs 6.10, or 1.24 percent on the BSE.

Posted by Rakesh Patil
X
Sections
Follow us on
Available On